Annual report pursuant to Section 13 and 15(d)

Note 21 - Supplemental Disclosure for Statements of Cash Flows

v3.19.1
Note 21 - Supplemental Disclosure for Statements of Cash Flows
 12 Months Ended
Dec. 31, 2018
Notes to Financial Statements  
Cash Flow, Supplemental Disclosures [Text Block]
2
1
.
Supplemental Disclosure for Statements of Cash Flows
 
During
2018
and
2017,
we paid interest aggregating
$8,000
and
$7.4
million, respectively. During
2017,
we issued
1
million Series NN warrants to UCSD with an estimated fair value of
$334,000.
During
2018
and
2017,
we issued
94,684
and
105,308
shares of our common stock, respectively, as matching contributions to our
401
(k) Plan which were valued at
$36,000
and
$54,000,
respectively. In
November 2018,
we prepaid
$393,000
of insurance premiums through the issuance of a note payable to IPFS with an interest rate of
5.1%.
In
November 2017,
we prepaid
$396,000
of insurance premiums through the issuance of a note payable to IPFS with an interest rate of
4.0%.
As discussed in Note
9,
the liability for the additional
$200,000
of investments made by Platinum was reclassified to additional paid-in-capital in
January 2017.
As discussed in Note
15,
in
November 2018,
the Company issued
18.5
million shares of common stock of Navidea to Dr. Goldberg, of which approximately
16.4
million shares valued at
$3.2
million were applied as payment of the Platinum debt, including principal and accrued interest of
$2.2
million and loss on extinguishment of debt of
$1.0
million.